Abstract：Respiratory mucosal immunity, the host?s first line of defense against Mycobacterium tuberculosis (MTB) infection, plays an essential role in protecting against MTB infection. Mucosal immunization to induce specific immunity in the mucosal immune system has become a new research direction in the novel tuberculosis vaccine areas. On the basis of recent studies on tuberculosis mucosal vaccines, this article summarizes the characteristics of different types of vaccines, immunological features and protective effects against MTB infection. In addition, future prospects for research on mucosal vaccines of tuberculosis are described, to guide more effective studies.
王丽梅. 结核病黏膜疫苗的研究进展[J]. 中国人兽共患病学报, 2022, 38(2): 170-174.
WANG Li-mei. Development of tuberculosis mucosal vaccines. Chinese Journal of Zoonoses, 2022, 38(2): 170-174.
[1] WHO. Global tuberculosis report2020[EB/OL]. (2021-06-30)[2021-08-10].https://www.who.int/teams/global-tuberculosis-programme/tb- reports [2] Rodrigues LC, Mangtani P, Abubakar I.How does the level of BCG vaccine protection against tuberculosis fall over time[J]. BMJ,2011,343:d5974. DOI: 10.1136/bmj.d5974 [3] Lai R, Afkhami S, Haddadi S, et al.Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments[J]. Eur Respir Rev,2015,24(136):356-360. DOI:10.1183/16000617.00002515 [4] Volz A, Sutter G.Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development[J]. Adv Virus Res,2017,97:187-243. DOI:10.1016/bs.aivir.2016.07.001 [5] White AD, Sibley L, Dennis MJ, et al.Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques[J]. Clin Vaccine Immunol,2013,20(5):663-672. DOI: 10.1128/CVI.00690-12 [6] Wang J, Thorson L, Stokes RW, et al.Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis[J]. J Immunol, 2004,173(10):6357-6365. DOI:10.4049/jimmunol.173.10.6357 [7] Santosuosso M, McCormick S, Zhang X, et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis[J]. Infect Immun, 2006,74(8):4634-4643. DOI: 10.1128/IAI.00517-06 [8] Xing Z, McFarl CT, Sallenave JM, et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis[J]. PLoS One, 2009,4(6):e5856. DOI: 10.1371/journal.pone.0005856 [9] Dean GS, Clifford D, Whelan AO, et al.Protection induced by simultaneous subcutaneous and endobronchial vaccination with BCG/BCG and BCG/Adenovirus expressing antigen 85A against Mycobacterium bovis in cattle[J]. PLoS One, 2015,10(11):e0142270. DOI: 10.1371/journal.pone.0142270 [10] Pérez de Val B, Villarreal-Ramos B, Nofrarías M, et al. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis[J]. Clin Vaccine Immunol, 2012,19(9):1339-1347. DOI: 10.1128/CVI.00275-12 [11] Jeyanathan M, Shao Z, Yu X, et al.AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-Primed non-human primates[J]. PLoS One,2015,10(8):e0135009. DOI: 10.1371/journal.pone.0135009 [12] Mu J, Jeyanathan M, Small CL, et al.Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis[J]. Mol Ther,2009,17(6):1093-1100. DOI: 10.1038/mt.2009.60 [13] Jeyanathan M, Thanthrige-Don N, Afkhami S, et al.Novel chimpanzee adenovirus- vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection[J]. Mucosal Immunol,2015,8(6):1373-1387. DOI: 10.1038/mi.2015.29 [14] Roediger EK, Kugathasan K, Zhang X, et al.Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine[J]. Mol Ther,2008,16(6):1161-1169. DOI: 10.1038/mt.2008.59 [15] Griesenbach U, Inoue M, Hasegawa M, et al.Sendai virus for gene therapy and vaccination[J].Curr Opin Mol Ther,2005,7(4):346-352. [16] Hu Z, Wong KW, Zhao HM, et al.Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice[J].Mol Ther, 2017,25(5):1222-1233. DOI:10.1016/j.ymthe.2017.02.018 [17] Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al.Progress in the development of human parainfluenza virus vaccines[J]. Expert Rev Respir Med,2011,5(4):515-526. DOI: 10.1586/ers.11.32 [18] Watanabe K, Matsubara A, Kawano M, et al.Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization[J]. Vaccine, 2014, 32(15):1727-1735. DOI: 10.1016/j.vaccine.2013.11.108 [19] Gerlach T, Elbahesh H, Saletti G, et al.Recombinant influenza A viruses as vaccine vectors[J]. Expert Rev Vaccines,2019,18(4):379-392. DOI: 10.1080/14760584.2019.1582338 [20] Khoshnood S, Heidary M, Haeili M, et al.Novel vaccine candidates against Mycobacterium tuberculosis[J].Int J Biol Macromol,2018, 120(Pt A):180-188. DOI: 10.1016/j.ijbiomac.2018.08.037 [21] Blazevic A, Eickhoff CS, Stanley J, et al.Investigations of TB vaccine-induced mucosal protection in mice[J].Microbes Infect,2014,16(1): 73-79. DOI: 10.1016/j.micinf.2013.09.006 [22] Hung JT, Huang JR, Yu AL.Tailored design of NKT-stimulatory glycolipids for polarization of immune responses[J]. J Biomed Sci,2017,24(1):22. DOI: 10.1186/s12929-017-0325-0 [23] Khan A, Singh S, Galvan G, et al.Prophylactic Sublingual Immunization with Mycobacterium tuberculosis subunit vaccine incorporating the natural killer T cell agonist alpha-galactosylceramide enhances protective immunity to limit pulmonary and extra- pulmonary bacterial burden in mice[J]. Vaccines (Basel),2017,5(4):47. DOI: 10.3390/vaccines5040047 [24] Ballester M, Nembrini C, Dhar N, et al.Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis[J]. Vaccine,2011,29(40): 6959-6966. DOI: 10.1016/j.vaccine.2011.07.039 [25] Hart P, Copland A, Diogo GR, et al.Nanoparticle-fusion protein complexes protect against Mycobacterium tuberculosis infection[J].Mol Ther,2018,26(3):822-833. DOI: 10.1016/j.ymthe.2017.12.016 [26] Li D, Fu D, Kang H, et al.Advances and potential applications of chitosan nanoparticles as a delivery carrier for the mucosal immunity of vaccine[J]. Curr Drug Deliv,2017,14(1):27-35. DOI: 10.2174/1567201813666160804121123 [27] Ahmed M, Jiao H, Domingo-Gonzalez R, et al.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice[J]. J Leukoc Biol,2017, 101(6):1373-1381. DOI: 10.1189/jlb.4A0616-270R [28] Luabeya AK, Kagina BM, Tameris MD, et al.First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults[J]. Vaccine,2015,33(33):4130-4140. DOI: 10.1016/j.vaccine.2015.06.051 [29] Thakur A, Rodríguez-Rodríguez C, Saatchi K, et al.Dual-isotope SPECT/CT imaging of the tuberculosis subunit vaccine H56/CAF01: induction of strong systemic and mucosal IgA and T-Cell responses in mice upon subcutaneous prime and intrapulmonary boost immunization[J]. Front Immunol, 2018, 9:2825. DOI: 10.3389/fimmu.2018.02825 [30] Andersen CS, Dietrich J, Agger EM, et al.The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis[J]. Infect Immun,2007,75(1):408-416. DOI: 10.1128/IAI.01290-06 [31] Copland A, Diogo GR, Hart P, et al.Mucosal delivery of fusion proteins with Bacillus subtilis FLA spores enhances protection against tuberculosis by Bacillus Calmette-Guérin[J]. Front Immunol,2018,9:346. DOI: 10.3389/fimmu.2018.00346 [32] Mustafa AD, Kalyanasundram J, Sabidi S, et al.Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice[J]. BMC Biotechnol,2018,18(1):63. DOI: 10.1186/s12896-018-0461-y [33] Woodrow KA1, Bennett KM, Lo DD. Mucosal vaccine design and delivery[J]. Annu Rev Biomed Eng,2012,14:17-46. DOI: 10.1146/annurev-bioeng-071811-150054 [34] Vajdy M, Singh M.The role of adjuvants in the development of mucosal vaccines[J]. Expert Opin Biol Ther,2005,5(7):953-965. DOI: 10.1517/14712598.5.7.953 [35] Srivastava A, Gowda DV, Madhunapantula SV, et al.Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles[J]. APMIS,2015,123(4):275-288. DOI: 10.1111/apm.12351 [36] Otczyk DC, Cripps AW.Mucosal immunization: a realistic alternative[J]. Hum Vaccin,2010, 6(12):978-1006. DOI: 10.4161/hv.6.12.13142
2022, Vol. 38 
